Contraline

High-Level Overview

Contraline is a medical device company developing ADAM™, a long-lasting, non-hormonal, and reversible male contraceptive implant using hydrogel technology, often described as the "male IUD."[1][2][3][4] The product targets men and couples seeking effective birth control without hormonal side effects; it serves by injecting a proprietary hydrogel (previously referenced as Echo-V) into the vas deferens via a minimally invasive outpatient procedure, blocking sperm while allowing fluid passage.[1][3] This solves the problem of limited male contraceptive options beyond condoms or vasectomy, aiming for 10+ years of efficacy with reversibility.[1][4] Headquartered in Charlottesville, Virginia, with about 10 employees, Contraline has raised funding through grants (e.g., $1M from Male Contraceptive Initiative in 2020), competition awards, private investment, and venture capital, and remains in the development stage with clinical trials underway.[1][2]

Origin Story

Contraline was founded in 2015 by Kevin Eisenfrats (Co-Founder and CEO) and Dr. John Herr, leveraging advancements in hydrogel technology for vas-occlusion.[1] Eisenfrats, with a background in medical device innovation, leads efforts focused on clinical translation and patient satisfaction; the company emerged from research addressing decades of failed attempts at non-hormonal male contraception.[1][3] Early traction included a $200K grant from the Male Contraceptive Initiative in 2018 and a $1M investment in 2020 to fund clinical trials, marking pivotal moments that propelled development of ADAM™.[1] Based at 1216 Harris Street in Charlottesville, the team has grown to support ongoing trials and hiring, such as for senior design engineers.[2]

Core Differentiators

• Non-hormonal and reversible hydrogel implant: ADAM™ (or Echo-V) is injected into the vas deferens, forming a semi-permeable barrier that blocks sperm without affecting hormones, hormones, or requiring surgery; it's ultrasound-visible for monitoring and designed for long-lasting (10+ years) contraception with removal for reversibility.[1][3][4]
• Minimally invasive procedure: Outpatient injection similar to a vasectomy but reversible, prioritizing safety, ease, and patient satisfaction over traditional methods.[1][3]
• Proprietary technology: Patent-pending polymer that's easily injectable, long-lasting, and focused on clinical readiness, distinguishing it from prior vas-occlusion failures.[1][3]
• Venture-backed development stage: Supported by targeted grants and VC, with a small, specialized team (10 people) in devices & instrumentation, enabling rapid iteration toward market.[2][5]

Role in the Broader Tech Landscape

Contraline rides the trend toward contraceptive equity and shared reproductive responsibility, addressing the market gap where women bear most long-acting options amid rising demand for male-involved birth control.[1][3] Timing aligns with maturing hydrogel tech and funding for male contraceptives, fueled by societal shifts post-#MeToo and clinical progress (e.g., ongoing trials).[1] Favorable forces include regulatory interest in non-hormonal innovations and a $20B+ global contraception market, where male options remain <10%.[1] The company influences the ecosystem by pioneering the "intra-vas device" (IVD), potentially spurring competitors and normalizing male contraception in medtech hubs like Charlottesville's BioHub.[2][3]

Quick Take & Future Outlook

Contraline's clinical trials position it for potential FDA clearance in the late 2020s, with next steps including trial expansion, reversibility data, and commercialization partnerships.[1] Trends like personalized medtech, ultrasound integration, and gender-balanced family planning will accelerate adoption, evolving its influence from niche innovator to catalyst in a male contraceptive market projected to grow 15%+ annually. As the "IUD for men" matures, Contraline could redefine contraception, empowering couples with truly shared options.[4]